Clinical Trials in Detroit

Showing 7021-7040 of 14,997 trials

A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT03650491

This study will test the safety and efficacy of FOR46 given every 21 days to patients with relapsed or refractory multiple myeloma. The name of the study drug involved in this study is: FOR46 for Injection

Multiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma With Failed Remission

Fortis Therapeutics, Inc.31 participantsStarted Apr 2019

San Francisco, California, United States • Aurora, Colorado, United States • Atlanta, Georgia, United States +4 more locations

COMPLETEDPhase 1< 1 mile

A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

NCT02684032

This is a multicenter, open label, Phase 1b study in patients with mBC. This study will have a dose escalation to identify the maximum tolerated dose (MTD) of the combination of gedatolisib plus palbociclib/fulvestrant and gedatolisib plus palbociclib/letrozole and expansion to estimate the objective response rate (OR) of the combination of gedatolisib plus palbociclib/letrozole or palbociclib/fulvestrant.

Breast Cancer

Celcuity Inc141 participantsStarted Jun 2016

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Corona, California, United States +38 more locations

A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

Find Trials by Condition in Detroit

Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis

Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma

A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1

Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia

Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms

The Effect of Riboflavin on Moderate to Severe Plaque Type Psoriasis

Comparing Parent-Implemented Interventions for Toddlers With Autism Spectrum Disorders

Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer

Serum and Urine Titanium Levels in Children With Early Onset Scoliosis Treated With Growth-Sparing Instrumentation

A Study of Immune Responses to the Virus That Causes COVID-19

Efficacy and Safety of AXA1665 in Cirrhotic Subjects With Prior Overt Hepatic Encephalopathy

Trial of 4-Hydroxytamoxifen (4-OHT) Gel in Women Aimed at Reducing Dense Breast Tissue

A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes

A Study of the Communication of Genetic Test Results By Telephone: A Multi-Center Study

Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Who Have an Inadequate Response to Eculizumab

Postprandial Glycemic Response in Adults With Type 2 Diabetes

Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV

Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors